Ocular Therapeutix (OCUL) Misses Q1 EPS by 13c

Ocular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.39), $0.13 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $13.37 million versus the consensus estimate of $14.07 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Arrive AI and DXC Technology partner to bring delivery tech to factories
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2